#BPaLM

The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbek... Treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB) and pre–extensively drug-resistant TB using 24-week all-oral bedaquiline, pretoman

Excellent work by @msf.ca @msfsci.bsky.social, @who.int, Uzbekistan and Belarusian colleagues on real world evidence for #BPaLM and #BPaLC 6 months treatment for rifampicin-resistant #TB @lshtmamrcentre.bsky.social @ucltb.bsky.social

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation This trial-based evidence adds to consistent indications from modelling studies that BPaL-based regimens are cost-saving for both the patient and health system. Urgent implementation of BPaL-based reg...

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation - The Lancet Global Health www.thelancet.com/journals/lan... #BPaLM for #TB more evidence. @catherineberry.bsky.social @lshtm.bsky.social